Fortitude Family Office LLC Buys 2,902 Shares of Boston Scientific Corporation $BSX

Key Points

• Fortitude Family Office LLC significantly increased its stake in Boston Scientific Corporation by 687.7%, now owning 3,324 shares valued at approximately $357,000 after acquiring an additional 2,902 shares in Q2.
• Multiple large investors, including GAMMA Investing LLC and Vanguard Group Inc., have also substantially increased their holdings in Boston Scientific in recent quarters.
• Boston Scientific reported a quarterly EPS of $0.75 for Q2, exceeding analysts' expectations, and a year-over-year revenue increase of 22.8% to $5.06 billion.

Fortitude Family Office LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 687.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,324 shares of the medical equipment provider's stock after purchasing an additional 2,902 shares during the quarter. Fortitude Family Office LLC's holdings in Boston Scientific were worth $357,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in BSX. GAMMA Investing LLC boosted its stake in Boston Scientific by 11,720.3% in the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after purchasing an additional 2,556,078 shares during the period. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock valued at $250,757,000 after acquiring an additional 1,536,663 shares in the last quarter. Finally, Swedbank AB raised its holdings in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock valued at $302,816,000 after acquiring an additional 1,505,019 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on BSX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a report on Friday. Robert W. Baird raised their price target on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Truist Financial raised their price target on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $118.04.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

BSX opened at $96.91 on Tuesday. The firm has a market cap of $143.60 billion, a price-to-earnings ratio of 57.69, a PEG ratio of 2.36 and a beta of 0.65. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The stock's 50 day simple moving average is $104.25 and its 200 day simple moving average is $102.08. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.